Unicycive Therapeutics Inc
unicycive.comWhat Do They Do?
Develops investigational kidney-disease therapies, including a phosphate binder for people with chronic kidney disease on dialysis and a drug candidate for acute kidney injury.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies to address…View ↗
Our current development programs are focused on two novel therapies: oxylanthanum carbonate, a next-generation phosphate binder for the…View ↗
Oxylanthanum carbonate (lanthanum dioxycarbonate) is an investigational next-generation lanthanum-based phosphate binding agent being…View ↗
How Do They Make Money?
$675K
-
10-K for FY2024, filed Mar 31, 2025
$675K ↗
Do Revenues Turn Into Profits?
No. It lost $30.5M in FY2023.
10-K for FY2024, filed Mar 31, 2025
−$20.8MView ↗
10-K for FY2024, filed Mar 31, 2025
−$30.5MView ↗
10-K for FY2024, filed Mar 31, 2025
−$18.3MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$1.7MView ↗
- ▼ −73% (Loss)
- vs −$6.4M in Q2 FY2025
Loading...
